X4 Pharmaceuticals (XFOR) Interest Expenses (2017 - 2025)

X4 Pharmaceuticals' Interest Expenses history runs 9 years deep, the most recent figure standing at $2.2 million for Q4 2025.

• Quarterly Interest Expenses fell 4.99% year-over-year to $2.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $8.9 million (up 1.27% YoY) and the FY2025 annual result came in at $214.2 million, up 15.83% from the prior year.
• Interest Expenses was $2.2 million for Q4 2025 at X4 Pharmaceuticals, down from $2.3 million in the prior quarter.
• Across five years, Interest Expenses topped out at $2.4 million in Q3 2024 and bottomed at $157000.0 in Q4 2022.
• A 5-year average of $1.6 million and a median of $1.8 million in 2023 frame the typical range for Interest Expenses.
• Annual changes were most pronounced in 2022 — Interest Expenses tumbled 93.17% — and 2023, when it soared 1101.27%.
• X4 Pharmaceuticals' Interest Expenses stood at $2.3 million in 2021, then tumbled by 93.17% to $157000.0 in 2022, then surged by 1101.27% to $1.9 million in 2023, then rose by 22.16% to $2.3 million in 2024, then declined by 4.99% to $2.2 million in 2025.
• Business Quant data shows XFOR's Interest Expenses at $2.2 million in Q4 2025, $2.3 million in Q3 2025, and $2.2 million in Q2 2025.